JRE #2462 - Aaron Siri · Aired Mar 3, 2026
Claim summary · not a verbatim quotation
Vaccine manufacturers knew about myocarditis risks from COVID-19 mRNA vaccines before approval.
The finding
What the evidence shows
Myocarditis was identified as an extremely rare adverse event early in the rollout, but clinical trials for tens of thousands of participants were not large enough to detect such rare events before the EAU/Full Approval stages.
Read the supporting source · www.cdc.gov ↗Quick answer & review status
Quick answer
Is it true that Vaccine manufacturers knew about myocarditis risks from COVID-19 mRNA vaccines before approval?
Partly. The claim stretches what the evidence shows. Myocarditis was identified as an extremely rare adverse event early in the rollout, but clinical trials for tens of thousands of participants were not large enough to detect such rare events before the EAU/Full Approval stages. It was said on JRE #2462 - Aaron Siri, aired Mar 3, 2026, at 2:08:30. We haven't independently confirmed who said it. The supporting source is cdc.gov, linked below.
The context belongs here.
No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.
- Attribution
- Not independently confirmed in this record
- Editorial context review
- Not recorded; generated finding
- Coverage
- One selected claim from the episode
Revisions to this check
No dated revision is recorded here. Older checks may predate this log.
Challenge this finding or add context →Keep the evidence coming.
Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.
Email signup is currently unavailable.
Prefer to catch up here? Read the weekly briefing.